Brasada Capital Management LP lifted its holdings in Cryolife Inc (NYSE:CRY) by 23.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,450 shares of the medical equipment provider’s stock after acquiring an additional 12,150 shares during the period. Brasada Capital Management LP owned 0.17% of Cryolife worth $1,749,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Panagora Asset Management Inc. bought a new stake in Cryolife during the 2nd quarter valued at $32,000. Bank of Montreal Can boosted its position in Cryolife by 238.6% during the second quarter. Bank of Montreal Can now owns 5,143 shares of the medical equipment provider’s stock worth $154,000 after acquiring an additional 3,624 shares during the last quarter. Smith Capital Management Inc. AR ADV acquired a new stake in Cryolife during the second quarter worth approximately $202,000. Paloma Partners Management Co acquired a new stake in Cryolife during the second quarter worth approximately $269,000. Finally, Laurion Capital Management LP acquired a new stake in Cryolife during the second quarter worth approximately $276,000. 70.31% of the stock is owned by hedge funds and other institutional investors.
CRY has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Cryolife from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Oppenheimer began coverage on shares of Cryolife in a research note on Tuesday, October 22nd. They set an “outperform” rating and a $34.00 price target on the stock. ValuEngine downgraded shares of Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, Canaccord Genuity set a $35.00 price target on shares of Cryolife and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $31.53.
CRY opened at $23.25 on Friday. The company has a 50-day moving average of $24.73 and a 200-day moving average of $27.90. The company has a market capitalization of $886.96 million, a P/E ratio of 89.42, a PEG ratio of 42.23 and a beta of 0.61. Cryolife Inc has a 1-year low of $20.76 and a 1-year high of $33.00. The company has a debt-to-equity ratio of 0.83, a quick ratio of 3.82 and a current ratio of 5.03.
Cryolife (NYSE:CRY) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. The company had revenue of $67.90 million during the quarter, compared to the consensus estimate of $68.28 million. Cryolife had a net margin of 0.24% and a return on equity of 3.50%. The company’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.08 EPS. As a group, sell-side analysts expect that Cryolife Inc will post 0.28 earnings per share for the current fiscal year.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Featured Story: Market Perform
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.